NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Len and Dex NDMM

NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

Elo-KRd

NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

This study will be a multi-center, open-label, Phase 2 study where newly diagnosed Multiple Myeloma requiring systemic chemotherapy will be eligible for enrollment. A total of 55 subjects will be enrolled. Time to progression or death will be calculated from the date of first treatment on protocol until the date of disease progression or death from any cause. Patients can expect to participate between 12-24 cycles. The primary endpoint will be the rate of response by next generation gene sequencing at the end of 8 cycles among non-transplant candidates and transplant candidates who agreed to defer transplant.

Sponsor:

University of Chicago

Collaborators:

Bristol-Myers Squibb

Amgen

Multiple Myeloma Research Foundation